Stocks recently featured in the blog include: Tesla, Inc. TSLA, Johnson & Johnson JNJ ... If also adjusted for the big Bristol Myers one-charge, the Q1 earnings growth improves to +12.1% on ...
🔍 Case Summary: The court rejected a legal challenge by Bristol Myers Squibb and Johnson & Johnson against a mandate requiring them to negotiate drug prices for their leading blood clot ...
Although a New Jersey federal judge last week dismissed the cases brought by Johnson & Johnson and Bristol Myers Squibb against the IRA ... If courts allow drug firms to challenge IRA price ...
The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. With 18 of the industry’s top 25 companies achieving year-over-year revenue gains, the ...
News Corp and OpenAI have established a historic partnership allowing OpenAI to use journalistic content from News Corp, ...
In addition, the SENTRY antimicrobial surveillance project, launched in 1997 with funding from Bristol Myers Squibb (Princeton ... currently collaborating with Johnson & Johnson (New Brunswick ...
In his final year at the helm of Bristol Myers Squibb, Giovanni Caforio ... details on its plans for its burgeoning oncology division a few weeks later. Johnson & Johnson CEO Joaquin Duato made $28.4 ...
NEW: Johnson & Johnson and Bristol Myers Squibb Co.'s bids to block a government drug price-setting program were dismissed by a federal judge Monday. Another loss to the pharmaceutical industry ...
Bristol-Myers Squibb faces a soft growth outlook, but high expected free cash flow and steady sales suggest today's valuation is simply too low. With a dividend yield now near 6%, I outline key ...
Myrtle T. (Taylor) Myers, 83, of Bristol, widow of George Myers, died Thursday (February 20, 2003) at Sheriden Woods Health Care Center. Mrs. Myers was born in Bristol on April 18, 1919 and was a ...
In trading on Wednesday, shares of Bristol Myers Squibb were yielding above the 6% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands as low as $39.94 on the day.
Bristol Myers Squibb is again dipping into the well of therapies being developed by Prothena, this time for an exclusive license to a neurodegenerative candidate that is about to slide into human ...